- Previous Close
61.76 - Open
61.39 - Bid 43.64 x 100
- Ask 74.75 x 100
- Day's Range
58.03 - 61.52 - 52 Week Range
45.56 - 103.81 - Volume
823,611 - Avg. Volume
933,255 - Market Cap (intraday)
3.292B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-1.75 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
93.86
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
www.procept-biorobotics.comRecent News: PRCT
View MorePerformance Overview: PRCT
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRCT
View MoreValuation Measures
Market Cap
3.29B
Enterprise Value
3.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.94
Price/Book (mrq)
8.18
Enterprise Value/Revenue
13.53
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-40.72%
Return on Assets (ttm)
-12.86%
Return on Equity (ttm)
-26.77%
Revenue (ttm)
224.5M
Net Income Avi to Common (ttm)
-91.41M
Diluted EPS (ttm)
-1.75
Balance Sheet and Cash Flow
Total Cash (mrq)
333.72M
Total Debt/Equity (mrq)
20.45%
Levered Free Cash Flow (ttm)
-78.24M